DALLAS Nov. 7, 2024 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Sunil Gupta, MD, has joined the Company’s Board of Directors. Dr. Gupta is a nationally recognized retinal surgeon and a successful entrepreneur who brings deep experience in all phases of drug development and medical devices, including commercialization and manufacturing.
“Dr. Gupta possesses an extraordinary combination of medical and entrepreneurial expertise around the treatment of inherited retinal diseases and dry age-related macular degeneration. He is a renowned, patient-focused physician, as well as an effective leader in executing clinical trials and operations. Dr. Gupta has truly advanced care for retina patients across the world. He will be an invaluable member of Nanoscope’s board as we advance towards commercialization of our mutation-agnostic therapies to restore vision in millions of people blinded by retinal diseases and dry-AMD,” said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope.
“Nanoscope continues to advance work on its groundbreaking gene therapies for inherited retinal diseases such as retinitis pigmentosa (RP) and Stargardt, offering hope to patients for whom no cure currently exists,” said Dr. Gupta. “The company’s recent announcements highlighting the efficacy and safety results from its randomized Phase 2b trial in RP with subsequent BLA submission are revolutionary. With a Phase 3 registrational trial for Stargardt and a BLA filing in RP on the horizon, Nanoscope is closer to helping address serious unmet needs. Nanoscope has assembled a world-class team of scientists, physicians and business leaders, and I am excited to contribute.”
“I want to extend a warm welcome to Dr. Gupta and look forward to working with him. He joins us at a pivotal moment in Nanoscope’s journey,” said Glenn Sblendorio, Chairman of the Board. “With an enhanced regulatory pathway, we look forward to utilizing his strategic expertise as well as his network with the retinal community.”
Dr. Gupta is founder and clinical principal investigator at Retina Specialty Institute (RSI), one of the largest retinal research organizations in los Estados Unidos serving patients in clinics across the south. He was also the founder and chief medical officer of USRetina—one of the largest associations of retina physicians in the United States specializing in drug distribution, GPO, and clinical operational processes and software development prior to its recent exit to McKesson. He founded and serves as chairman and chief medical officer of Intelligent Retinal Imaging Systems (IRIS), an FDA-cleared, cloud based, telemedicine platform for assessment of retinal eye disease in the primary care setting. Dr. Gupta’s IRIS team is working to end preventable blindness due to diabetic retinopathy and other conditions around the world. Dr. Gupta was the past chairman of the Andrews Institute Sports Medicine Center and served on the board of the Andrews Research & Education Institute. In these efforts and beyond, he bridges industry and clinical care delivery organizations to optimize patient experience and outcomes. Dr. Gupta earned his medical degree from the Universidad de Cincinnati Facultad de Medicina y completó su residencia en Oftalmología en el Cullen Eye Institute en Facultad de Medicina de Baylor en Houston, TexasCompletó una beca en Enfermedades y Cirugía Vítreo-Retiniana en la Universidad de Iowa.
Acerca de Nanoscope Therapeutics Inc.
Nanoscope Therapeutics está desarrollando terapias optogenéticas que restauran la visión y que no dependen de los genes para los millones de pacientes que han perdido la visión a causa de enfermedades degenerativas de la retina, para las que no existe cura. El principal activo de la empresa, MCO-010, informó recientemente los resultados principales del ensayo clínico RESTORE de fase 2b, multicéntrico, aleatorizado, de doble ciego y controlado con placebo en los EE. UU. para la retinitis pigmentosa (NCT04945772). La empresa ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con Stargardt (NCT05417126) y recientemente anunció planes para iniciar una Fase 3 Ensayo de registro en el primer trimestre de 2025. MCO-010 ha recibido designaciones de vía rápida de la FDA y designaciones de medicamento huérfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos preclínicos incluyen la terapia génica MCO-020 administrada con láser no viral para la atrofia geográfica. Contacto de inversores:
Socios Argot
(212) 600-1902
PR@nanostherapeutics.com FUENTE Terapéutica del Nanoscopio
Nanoscope Therapeutics está desarrollando terapias optogenéticas que restauran la visión y que no dependen de los genes para los millones de pacientes que han perdido la visión a causa de enfermedades degenerativas de la retina, para las que no existe cura. El principal activo de la empresa, MCO-010, informó recientemente los resultados principales del ensayo clínico RESTORE de fase 2b, multicéntrico, aleatorizado, de doble ciego y controlado con placebo en los EE. UU. para la retinitis pigmentosa (NCT04945772). La empresa ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con Stargardt (NCT05417126) y recientemente anunció planes para iniciar una Fase 3 Ensayo de registro en el primer trimestre de 2025. MCO-010 ha recibido designaciones de vía rápida de la FDA y designaciones de medicamento huérfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos preclínicos incluyen la terapia génica MCO-020 administrada con láser no viral para la atrofia geográfica. Contacto de inversores:
Socios Argot
(212) 600-1902
PR@nanostherapeutics.com FUENTE Terapéutica del Nanoscopio